Sengenics Strengthens Commitment to Cancer Diagnostics and Treatment Development, Becomes Oslo Cancer Cluster Member

Share Article

Sengenics plans to leverage on its KREX™ technology towards the Oslo Cancer Cluster's efforts in accelerating research and development in oncoproteomics for cancer biomarker discovery.

Sengenics, the functional proteomics company, today announced joining the Oslo Cancer Cluster, a strategic partnership that aims to further accelerate research and development in oncoproteomics for cancer biomarker discovery.

"We are very pleased to welcome Sengenics as a new member of the Oslo Cancer Cluster. Sengenics has unique domain expertise in functional proteomics that will complement the ecosystem towards realising cancer precision medicine," said Ketil Widerberg, General Manager of the Oslo Cancer Cluster.

The Oslo Cancer Cluster consists of 90 institutions, which include top tier universities like the University of Oslo (UiO) and pharmaceutical companies such as Bayer and Novartis, as well as other companies that have cutting edge technologies for cancer research. Sengenics therefore fits this ecosystem by providing its KREX™ technology which utilises BCCP as a folding marker and protein solubility enhancer. The success rate for expression of correctly folded and soluble proteins using KREX™ exceeds 98%. The technology can be applied in a highly parallelised pipeline resulting in high-throughput, highly consistent production of full-length, correctly folded and functionally validated proteins for autoantibody biomarker discovery. The KREX™ technology has also been used for making custom protein arrays for vaccine target identification, protein-protein interactions and on-array functional assays for drug screening.

Dr Arif Anwar, CEO of Sengenics said, "With healthcare comprising 5.8% of Norway's total sovereign fund investment, Norway is well positioned to be able to further drive research innovation in its healthcare holdings, with its profits being used to fund organisations like the Oslo Cancer Cluster. Their role in the EU-funded PERMIDES project and hosting of the Norwegian Immuno-Oncology Consortium has been crucial in extending the frontiers of cancer research."                                                                                                                                                                        

Sengenics is actively involved in research on 17 different cancers and has 5 patent applications involving the discovery of multiple autoantibody biomarkers in the early diagnostics, staging and therapeutics of cancer. The company has a significant track record in securing collaborations with high-level international institutions, including 8 of the top 10 global pharmaceutical companies and top-tier universities such as Harvard and MIT.

The KREX™ technology is the first in the world to consistently produce correctly folded and functionally verified proteins that preserves both linear and conformational epitopes. Its unique advantages mean that KREX™-derived products such as the Immunome protein array can provide an exceptionally clean signal, enhancing the quality of research at all stages for cancer research and drug discovery.

About Oslo Cancer Cluster
The Oslo Cancer Cluster is a research-based industry cluster that brings together enterprises, organisations, academic and research institutions in the field of life science and converging industries like ICT to accelerate the development of cancer diagnosis and treatment. The members of the Oslo Cancer Cluster will perform research and development to establish new knowledge and generate novel products and services including innovative solutions between research and business entities. Oslo Cancer Cluster will contribute with competence to support its members at all innovation phases, from early stage development to commercialisation.

About Sengenics
Sengenics is a functional proteomics company that leverages its patented KREX™ technology for production of full-length, correctly folded and functional proteins. KREX™ is a patented proteomics technology which was spun out from research that was commercialised as a joint collaboration between the University of Oxford and the University of Cambridge. The three key applications of the KREX™ technology are; discovery of autoantibody biomarkers for human diseases, autoantibody-based immunotoxicity profiling of cancer immunotherapy patients and pharmaceutical industry-specific applications such as high-throughput SAR screening, predictive toxicology and antibody generation using KREX™ proteins.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Farah Elena
Sengenics
+60 127198656
Email >
Visit website